Cargando…
Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4
Hereditary cancers derive from gene defects that often compromise DNA repair. Thus, BRCA-associated cancers are sensitive to DNA-damaging agents such as cisplatin. The efficacy of cisplatin is limited, however, by the development of resistance. One cisplatin resistance mechanism is restoration of ho...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cold Spring Harbor Laboratory Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358401/ https://www.ncbi.nlm.nih.gov/pubmed/25737278 http://dx.doi.org/10.1101/gad.256214.114 |